TUBERCOLOSIS Agis Terzidis, Paediatrician Spyridon Gialamas, Medical Doctor SEMINAR ON TROPICAL AND...
-
date post
20-Dec-2015 -
Category
Documents
-
view
217 -
download
4
Transcript of TUBERCOLOSIS Agis Terzidis, Paediatrician Spyridon Gialamas, Medical Doctor SEMINAR ON TROPICAL AND...
TUBERCOLOSISAgis Terzidis, Paediatrician Spyridon Gialamas, Medical Doctor
SEMINAR ON TROPICAL AND TRAVEL MEDICINE AT TTCIH
IFAKARA 25 JUNE 2009
Estimated TB incidence rates, by country, 2007
Source: WHO
Trends in estimated incidence rates in nine subregions, 1990-2007
Source: WHO
Progress towards the 70% case-detection target
Source: WHO
Tuberculosis supranational reference laboratory network, 2007
Source: WHO
Countries that had reported at least one case of extensively drug-resistant TB
Source: WHO
Global Fund commitments for TB control by region, as of end 2008
Western Pacific Region20% (US$ 755 million)
African Region29% (US$ 1131 million)
Southeast Asia Region22% (US$ 867 million)
European Region13% (US$ 502 million)
Region of the Americas6% (US$ 229 million)
Eastern Mediterranean Region10% (US$ 382 million)
Source: WHO
Objectives for 2006–2015 of the WorkingGroup on New TB Diagnostics:
• address existing gaps in knowledge that are obstructing development of new diagnostic tools
• develop and evaluate a portfolio of new diagnostic tools and demonstrate their impact
• implement new diagnostic tools and ensure access to them
Source: WHO
Strategic plan for 2006–2015 of the WorkingGroup on New TB Drugs:
• Identification and validation of new targets for drugs, and candidate compounds
• drug development• planning and execution of more effective clinical trials,
including identification of improved biomarkers and methods of assessing latent disease
• clear and efficient regulatory guidance
Source: WHO
Strategic plan for 2006–2015 of the WorkingGroup on TB Vaccines:
• maintain and improve BCG vaccination programmes. The next generation of new vaccines introduced as an addition to BCG vaccines
• expand discovery and translation research on vaccines (“keeping the pipeline filled”)
• facilitate preclinical development of new vaccines• build capacity at vaccine trial sites, providing opportunities
for training and capacity strengthening
AHSANTENI